In order to boost international connection and strive for business opportunities, Deputy Convener Tsung-tsong Wu of the Board of Science and Technology, Executive Yuan led Taiwan delegation to partake in the BIO 2022 Conference from June 13-16, 2022. KMU start-up, PrecisemAb Biotech Co., Ltd. (PrecisemAb) represented Taiwan and competed with other companies for championship at San Diego Convention Center. It was the first time that Taiwan's team entered the final of Start-Up Stadium since its debut in 2017, according to Taiwan Tech Arena.

The SelectUSA Investment Summit is the premier event dedicated to promoting foreign direct investment in the United States. Early-stage and startup tech companies from across the world had the opportunity to virtually exhibit their products and tell their stories in June 26-29, 2022. PrecisemAb also made effort to present at the event for championship and more business opportunities.

PrecisemAb (https://www.precisemab.com.tw/Home) was established by KMU Professor Tien-Lu Cheng, Dr. YunChi Lu, Dr. YiAn Cheng and lab members. Professor Cheng has cultivated in antibody engineering for over 25 years and his original ‘‘Universal Antibody Lock’’ technology can effectively enhance antibody’s selectivity for diseases and reduce adverse effects caused by antibody drugs. This innovative technology represents a revolutionary breakthrough in biotechnology industry.